ADC Therapeutics/ADCT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About ADC Therapeutics

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Ticker

ADCT

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Ameet Mallik

Employees

273

Headquarters

Epalinges, Switzerland

ADC Therapeutics Metrics

BasicAdvanced
$330M
Market cap
-
P/E ratio
-$2.77
EPS
1.62
Beta
-
Dividend rate
$330M
1.61557
$6.04
$0.36
577K
4.608
4.354
-4.14%
-56.99%
-69.99%
4.808
-62.38%
-9.41%

What the Analysts think about ADC Therapeutics

Analyst Ratings

Majority rating from 7 analysts.
Buy

ADC Therapeutics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-258.88% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$18M
-74.10%
Net income
-$47M
-80.58%
Profit margin
-258.88%
-25.03%

ADC Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0.78%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.58
-$0.58
-$1.03
-$0.56
-
Expected
-$0.46
-$0.63
-$0.50
-$0.56
-$0.44
Surprise
26.87%
-8.55%
104.77%
0.78%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for ADC Therapeutics stock?

ADC Therapeutics (ADCT) has a market cap of $330M as of June 17, 2024.

What is the P/E ratio for ADC Therapeutics stock?

The price to earnings (P/E) ratio for ADC Therapeutics (ADCT) stock is 0 as of June 17, 2024.

Does ADC Therapeutics stock pay dividends?

No, ADC Therapeutics (ADCT) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next ADC Therapeutics dividend payment date?

ADC Therapeutics (ADCT) stock does not pay dividends to its shareholders.

What is the beta indicator for ADC Therapeutics?

ADC Therapeutics (ADCT) has a beta rating of 1.62. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the ADC Therapeutics stock price target?

The target price for ADC Therapeutics (ADCT) stock is $10, which is NaN% below the current price of $. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell ADC Therapeutics stock

Buy or sell ADC Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing